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Abstract: Preterm birth is strongly associated with neonatal death and long-term   neurological 
morbidity. The purpose of tocolytic drug administration is to postpone threatening preterm 
delivery for 48 hours to allow maximal effect of antenatal corticosteroids and maternal trans-
portation to a center with specialized neonatal care facilities. There is uncertainty about the 
value of atosiban (oxytocin receptor antagonist) and nifedipine (calcium channel blocker) as 
first-line tocolytic drugs in the management of preterm labor. For nifedipine, concerns have 
been raised about unproven safety, lack of placebo-controlled trials, and its off-label use. The 
tocolytic efficacy of atosiban has also been questioned because of a lack of reduction in neonatal 
morbidity. This review discusses the available evidence, the pros and cons of either drug and 
aims to provide information to support a balanced choice of first-line tocolytic drug: atosiban 
or nifedipine?
Keywords: atosiban, oxytocin receptor antagonist, nifedipine, calcium channel blocker, preterm 
birth, tocolytic drugs, preterm labor
Introduction
Preterm birth is responsible for approximately 75% of all neonatal deaths and 50% of 
childhood neurological morbidities.1,2 Preterm birth is also associated with both high 
immediate and long-term costs after discharge from the hospital.3 Infants born at less 
than 28 weeks spend 85 times as long in hospital as full-term babies in the first 5 years 
of life, with substantial healthcare costs. Over recent decades, the frequency of preterm 
birth in most Western countries seems to be increasing rather than decreasing.4,5 This 
increase cannot be explained by an increase in assisted conceptions, multiple preg-
nancies and elective deliveries. Perinatal death and morbidity are not only strongly 
related to early gestational age but are also related to whether or not steroids have been 
administered antenatally and the preterm infant has been transferred to a tertiary care 
centre in utero or ex utero.6 Therefore, postponing delivery for 48 hours in order to 
allow maximal effect of maternal parenteral steroid administration and transportation 
of the mother to a center with neonatal intensive care unit (NICU) facilities are the 
primary indications to treat women with tocolytic drugs diagnosed with a threatening 
preterm delivery. However, tocolytic drugs used for inhibition of acute preterm labor 
have not been shown to be very effective.7
In most countries, drugs registered for tocolysis are restricted to the β-adrenergic-
receptor agonist ritodrine and the oxytocin receptor antagonist atosiban. The literature 
does not support the efficacy of magnesium sulfate and most authors call for discontinu-
ation of the use of magnesium sulfate as a labor-inhibiting agent, which leaves only International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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cyclo-oxygenase inhibitors and calcium channel blockers as 
off-license alternatives.8–10 The use of β-adrenergic-receptor 
agonists as first-line tocolytic agents has decreased due to 
the high incidence of maternal adverse effects.11,12 Concerns 
regarding adverse effects of cyclo-oxygenase inhibitors on 
the fetal kidneys and ductus arteriosus, the increased risk 
of neonatal intraventricular hemorrhage, and necrotizing 
enterocolitis associated with this treatment, have limited its 
use.13,14 When compared to β-adrenergic-receptor agonists, 
the oxytocin receptor antagonist atosiban has fewer mater-
nal adverse effects with comparable efficacy (relative risk 
[RR] 1.07; 95% confidence interval [CI] 0.98 to 1.17).12,15,16 
However, atosiban has not been found to reduce the incidence 
of respiratory distress syndrome, a serious complication of 
prematurity, when compared to placebo.16 Calcium channel 
blockers appear to be more effective in postponing preterm 
delivery (RR 0.76; 95% CI 0.59 to 0.99) and reducing 
  neonatal respiratory distress (RR 0.64; CI 95% 0.45 to 0.91) 
than β-adrenergic-receptor agonists.17,18 However, placebo-
controlled nifedipine trials are not available.
Since the introduction of the oxytocin antagonist atosiban, 
the choice of first-line tocolytic drugs for the treatment of pre-
term labor is the subject of controversy in many papers. Some 
authors are concerned about the inconclusive information 
regarding the relative safety of calcium antagonists, such as 
nifedipine.19,20 Other authors question the tocolytic efficacy of 
atosiban, especially compared to nifedipine.17,21 This review 
discusses the available evidence to support a choice in type 
of first-line tocolytic drug, atosiban or nifedipine?
Tocolytic efficacy
The tocolytic efficacy of the oxytocin antagonist atosiban 
was established in 6 large randomized controlled double-
blind trials.12,15,22–25 Meta-analysis of these trials showed 
a small although significant increase in the proportion of 
women undelivered by 48 hours who had received atosiban 
compared to placebo (RR 1.13; 95% CI 1.02 to 1.26).16 
However, this conclusion was not supported by a Cochrane 
meta-analysis by Papatsonis and co-workers.21 They found no 
differences between atosiban and placebo or between atosi-
ban and β-adrenergic-receptor agonists in terms of tocolytic 
efficacy and neonatal outcomes.
Calcium channel blockers (CCB), registered as antihyper-
tensive drugs, are used extensively for treatment of premature 
labor. In a Cochrane meta-analysis by King and colleagues, 
CCB were compared with mainly β-adrenergic-receptor 
agonists.17 CCB reduced the number of women giving birth 
within 7 days after receiving treatment (RR 0.76; 95% CI 
0.60 to 0.97) and before 34 weeks of gestation (RR 0.83; 
95% CI 0.69 to 0.99).17 The results of this meta-analysis are 
based, for a large part, on one randomized controlled trial 
comparing nifedipine and ritodrine.18 Noticeably, this is 
the only large tocolytic trial to our knowledge presenting a 
reduction in neonatal respiratory distress syndrome. Whether 
this reduction is due to the tocolytic superiority of nifedipine 
remains uncertain. Nifedipine placebo-controlled trials have 
never been published. Large randomized controlled trials 
comparing atosiban and nifedipine directly are lacking.
However, 2 smaller studies comparing atosiban and 
nifedipine showed no differences in postponing preterm 
delivery.26,27 The first and largest, by Kashanian and 
  colleagues, enrolled 80 women with preterm contractions 
between 26 and 34 weeks of gestation. Atosiban was effec-
tive in 82.5% of cases (not delivered within 48 hours) and 
nifedipine in 75%, with a mean duration of pregnancy 
after treatment of 29 and 23 days (P = 0.79), respectively. 
Coomarasamy and   colleagues published an indirect com-
parison method to analyze randomized controlled trials 
of nifedipine and atosiban by using β-adrenergic-receptor 
agonists as common comparator, with the preservation of the 
randomization process.28 The analysis showed no   significant 
differences in efficacy in delaying delivery between nife-
dipine and atosiban. The limited evidence available   suggests 
no large differences in tocolytic efficacy comparing atosiban 
and nifedipine; however, a direct comparison in a large pow-
ered randomized controlled trial is necessary to establish 
possible superiority of either tocolytic agent.
Fetal effects
Atosiban crosses the placenta in an average fetal versus 
maternal ratio of 0.124.29 Drug concentrations in the fetal cir-
culation do not increase with longer infusion rates, suggesting 
that the drug does not accumulate in the fetus.29 Atosiban 
does not significantly alter maternal or fetal cardiovascular 
parameters when it is administered to late pregnant sheep.30 
In chronically instrumented baboons during the last third 
of pregnancy, an atosiban infusion did not alter fetal oxy-
genation.31 The fetal concerns regarding the use of atosiban 
mostly discussed in literature are based on the results of the 
atosiban versus placebo trial by Romero and co-workers.23 
They found a higher rate of fetal-infant deaths in the atosiban-
treated group compared to placebo. However, 7 of the 
10 infant deaths were newborns with birth weights ,0.650 kg 
suggesting that extreme prematurity played a rather large 
role in these adverse outcomes. Romero and colleagues 
hypothesized that the anti-vasopressin effects of atosiban International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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could have contributed to the poor outcome through pos-
sibly altered fetal responses to stress or insults.23,32 To date, 
evidence to support this hypothesis is lacking.   Furthermore, 
the trials comparing atosiban with beta-agonists showed a 
comparable neonatal outcome.12,22
Nifedipine easily crosses the placenta with a fetal versus 
maternal ratio of 0.93 between umbilical cord blood and 
maternal serum concentrations.33,34 Some animal studies 
report changes in uterine blood flow and fetal acidosis 
after CCB administration.35–39 Harake and colleagues 
found decreased uterine blood flow and lower fetal arterial 
  oxygen content in instrumented pregnant sheep treated with 
nifedipine infusion.35 However, in contrast, Holbrook and 
colleagues administered a single bolus of nicardipine to 
instrumented sheep and found no changes in uterine blood 
flow and fetal arterial oxygen content.36 They suggested 
that fetal acidosis after CCB infusion is primarily due to 
a decrease in uterine blood flow rather than a direct fetal 
effect of the drug. Blea and colleagues infused instrumented 
sheep with low dose nifedipine corresponding with human 
concentrations.37 They found hypoxia and acidosis in the 
sheep fetus without persistent decreases in uteroplacental or 
fetoplacental blood flows or blood pressures.
Most studies in humans show no decrease in uterine 
blood flow after nifedipine administration to pregnant 
women.38–42 Moretti and colleagues and Hanretty and colleagues 
found no changes in uterine and fetal Doppler flow velocity 
waveforms after oral nifedipine therapy in hypertensive preg-
nant women.38,40 Other studies have reported on normotensive 
women and the short-time effects (15 minutes, 1 hour, 3 hours 
and 5 hours) of oral nifedipine administration on fetal Dop-
pler flow velocity waveforms.41–44 One study found a transient 
decrease in umbilical artery pulsatility index (PI) 15 minutes 
after 10 mg sublingual nifedipine.43 The other studies found no 
changes in the fetal or uteroplacental circulation.41,42,44 Guclu 
and colleagues were the first to study fetal Doppler indices dur-
ing 48 hours of nifedipine tocolysis.44 They found no changes 
in umbilical artery PI during treatment, although they did find 
decreased uterine artery PI and middle cerebral artery PI at 
24 hours and 48 hours of treatment. We recently studied the 
direct effects of atosiban or nifedipine on fetal movement, 
fetal heart rate and fetal blood flow, yet found no effect of 
either tocolytic on the fetal biophysical profile.47 A Cochrane 
review of CCB for inhibiting preterm labor concluded that 
neonatal outcome was improved compared to beta-mimetics.17 
Oei and coworkers followed up 48 children in utero exposed 
to nifedipine at 9 to 12 years of age.48 No negative effects on 
psychosocial and motor functioning were found.
Maternal effects
In comparison with β-adrenergic receptor agonists, atosiban 
and nifedipine showed less side effects.10,12,15,18 Most com-
monly reported adverse drug reactions (ADR) of atosiban in 
these studies were headache, vomiting and nausea, occurring 
in about 10% of the patients. Nifedipine exerts both vascular 
and cardiac effects. It vasodilates the vessels and exerts nega-
tive inotropic and chronotropic effects depressing the heart.45 
The cardiodepressant effect of nifedipine in vivo is counter-
acted by a vasodilatation-triggered and baroreceptor mediated 
reflex increase in sympathic tone resulting in indirect cardio-
stimulation. The increase in sympathic tone compensates for 
the negative inotropic and chronotropic action by nifedipine 
on the heart. These mechanisms are most likely the basis for 
the ADR seen with nifedipine tocolysis. Most common ADR 
due to the vascular and cardiac effects of nifedipine are: 
hypotension; tachycardia; flushes; headache; increased liver 
enzymes; nausea and dizziness.46,47 Most of the randomized 
controlled trials on nifedipine for tocolysis have started with 
immediate-release tablets or capsules up to a maximum dose 
of 40 mg during the first hour. The extended-release medica-
tion varied between studies from 60 to 160 mg daily.10,18,46,48 
These trials report only minor or no reductions in diastolic 
or systolic blood pressure in normotensive pregnant women 
during the tocolysis extended-release regimen. Two studies 
focusing on the short term effects of nifedipine in normoten-
sive pregnant women found hypotension accompanied with 
tachycardia 45 minutes after nifedipine administration.41,49 
Randomized studies of tocolytic drugs have generally been 
restricted to well-defined (low risk) populations, excluding 
multiple gestations, preterm premature rupture of mem-
branes (PPROM), vaginal blood loss, maternal diabetes, 
or a history of cardiovascular disease. It is, therefore, dif-
ficult to translate these results to the general population of 
women with preterm labor. In recent years, several serious 
ADRs were published for women treated with CCB.20,50–59 
Analysis of these case reports is hampered by the fact that 
it is uncertain whether these serious ADRs were solely due 
to CCB administration and/or to co-medication. Moreover, 
these cases provide no indication as to the incidence of 
these ADRs. To study the prevalence of serious maternal 
ADRs with the use of the various tocolytic drugs in a gen-
eral population, we recently performed a prospective cohort 
study in the Netherlands and Belgium in a normal clinical 
setting.60 The participating hospitals registered, during one 
year, consecutive women who were treated with tocolytic 
drugs for preterm labor. In this period, 1920 women were 
treated with tocolytic drugs. Twenty-eight cases fulfilled the International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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study definition of an ADR; 14 cases were categorized as 
serious ADR and 14 as mild ADR. Serious ADR consisted 
of severe dyspnea (n = 6), hypotension (n = 4), lung edema 
(n = 2), hypoxia (n = 1) and cardiac failure (n = 1). The overall 
incidence of serious ADR was relatively low (0.7%). In 1327 
women treated with a single tocolytic drug the incidence of 
serious ADR was 1.7% for betamimetic drugs and 0.9% for 
nifedipine; no serious ADR were registered with the use of 
a single course of atosiban. When compared to atosiban, the 
number needed to prevent one serious ADR for β-adrenergic 
receptor agonists was 59 (95% CI lower limit 35) and the 
number needed to prevent one serious ADR for nifedipine 
was 109 (95% CI lower limit 56).
When combined courses (ie, when a patient was treated 
with multiple tocolytic drugs at the same time) were given in 
16.2% of all patients the incidence of severe ADR was high 
(1.6% to 2.5%). The study also showed 4 ADRs in women 
with a multiple gestation (n = 414), in 2 women receiving 
a single course of nifedipine and in 2 women treated with 
combined courses; However, these incidences were not statis-
tically significant. Whether this was due to lack of statistical 
power is uncertain.
Our study confirmed the high rate of ADR of β-adrenergic-
receptor agonists. Furthermore, the use of combined courses 
of tocolytics led to a high rate of serious ADR. We found no 
serious ADR after a single course treatment with atosiban. 
The overall incidence of serious ADR with the use of a single 
course nifedipine was relatively low in singleton pregnancies, 
although serious ADR did occur with this medication.
Conclusion
Tocolytic drugs have not been shown to be very effective 
or to improve fetal outcome. However, tocolysis is applied 
with the aim of postponing delivery for 48 hours, to allow 
for maximal effect of maternal parenteral steroid administra-
tion and transportation of the mother to a center with NICU 
facilities. The choice of the first-line tocolytic agent in terms 
of safety, effectiveness and costs is a topic of debate. An 
ideal tocolytic should postpone delivery without maternal 
and fetal side effects at low costs. Unfortunately, none of 
the tocolytics described above fulfils all these criteria. In 
this review we focused on the oxytocin antagonist atosiban 
and the calcium antagonist nifedipine. Although nifedipine 
crosses the placenta easily, no human studies have shown any 
adverse fetal or neonatal effects to date. The overall incidence 
of maternal serious adverse tocolytic drug reactions with the 
use of a single course nifedipine (not combined with other 
tocolytic drugs) in singleton gestation appears to be low, but 
not absent. The oral route of administration, low costs and 
a possible efficacy in reducing neonatal morbidity (shown 
in one large study) favor the use of CCBs. Atosiban has the 
best maternal and fetal safety profile; however, its costs are 
considerable. Many large randomized (placebo) controlled 
trials are available suggesting tocolytic efficacy but a reduc-
tion in neonatal morbidity was never found.
A direct comparison between oxytocin antagonists 
and CCBs in terms of tocolytic efficacy and effects on 
neonatal outcome is necessary. Moreover, larger studies with 
different nifedipine dose regimens are necessary to compare 
efficacy and maternal side effects.
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